Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

Published:2019-02-23 Issue:1 Volume:220 Page:46-56
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Anywaine Zacchaeus¹,Whitworth Hilary²³,Kaleebu Pontiano¹,Praygod George⁴,Shukarev Georgi⁵,Manno Daniela²,Kapiga Saidi²³,Grosskurth Heiner²³,Kalluvya Samuel⁶,Bockstal Viki⁵,Anumendem Dickson⁵,Luhn Kerstin⁵,Robinson Cynthia⁵,Douoguih Macaya⁵,Watson-Jones Deborah²³

Affiliation:

1. Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda

2. London School of Hygiene and Tropical Medicine, London, United Kingdom

3. Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania

4. Mwanza Research Center, National Institute for Medical Research, Mwanza, Tanzania

5. Janssen Vaccines and Prevention, Leiden, the Netherlands

6. Bugando Medical Center, Mwanza, Tanzania

Funder

EBOVAC 1

EBOVAC 2

EBOMAN

BODAC

Janssen Vaccines and Prevention,

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/220/1/46/28767091/jiz070.pdf

Reference31 articles.

1. Epidemiology of ebolavirus disease (EVD) and occupational EVD in health care workers in Sub-Saharan Africa: Need for strengthened public health preparedness;Ngatu;J Epidemiol,2017

2. How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence;Nyakarahuka;BMC Infect Dis,2016

3. The evolution of Ebola virus: Insights from the 2013-2016 epidemic;Holmes;Nature,2016

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico;Biotechnology and Applied Biochemistry;2024-08-11

2. Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo;Vaccines;2024-07-23

3. Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial;The Journal of Infectious Diseases;2024-07-16

4. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial;The Lancet Infectious Diseases;2024-07

5. Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial;Vaccines;2024-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3